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Abstract
Background: HCC is the fifth most common cancer globally. Our study was conducted to (1)investigate the trends
and clinico-pathological characteristics of Hepatocellular carcinoma among native South Asian patients in Pakistan,
(2)to estimate the prevalence as well as the trends of viral marker negative HCC and (3) to compare the clinico-
pathological, radiological characteristics, applicability of treatment at diagnosis and prognostic factors among
patients with both viral marker negative and viral marker positive-HCC being consulted at Aga Khan University
Hospital(AKUH), Karachi, Pakistan.
Method: Patients ≥18 years, already diagnosed to have HCC and visiting AKUH during 1999–2009 were identified
using ICD code 1550. The diagnosis of HCC was made in the presence of characteristic features of HCC on triple-
phasic CT scan/MRI or with histological findings on biopsy.
Results: 645 patients were enrolled. Of these 546(84.7%) were viral-HCC and 99(15.3%) were viral marker negative
HCC. Among viral-HCC group underlying etiology of cirrhosis was HCV in 67.9%, HBV in 21.8% and concomitant
HBV with HCV or HDV in 10.3% cases. Majority (62.8%) patients had advanced HCC. Larger tumor size (p < 0.001),
shorter duration between diagnosis of cirrhosis and HCC (p 0.03), concomitant Diabetes Mellitus (p < 0.001) were
found significant factors associated with viral marker negative HCC.
Conclusion: The burden of hepatocellular carcinoma is rising among native South Asian Pakistani population and
the viral marker negative HCC are not uncommon in our population. Viral marker negative HCC tend not to be
under surveillance as compared to viral-HCC and are diagnosed mostly at advanced stage & when they became
symptomatic.
Keywords: Hepatocellular Carcinoma, Viral marker negative HCC, Viral-HCC, Hepatitis B, Hepatitis C, Pakistan
Background
Despite advancements in the management of cirrhosis,
the prevalence of hepatocellular carcinoma (HCC) is on
the rise [1]. The prevalence of HCC varies geographically
and currently HCC is the fifth most common cancer
representing almost 6% of all newly diagnosed cancers
globally [2]. It is also one of the common causes of
mortality in patients with cirrhosis. Up to 80% of HCC
has been reported from South-East Asia and Africa
[2,3]. Hepatitis B (HBV) and C (HCV) are the most im-
portant risk factors predisposing a patient to having
HCC, particularly in Asia [4,5]. However, several patients
develop HCC due to the causes other than hepatitis B
and C. Therefore, patients who have negative serological
markers for hepatitis B and C grouped as viral marker
negative or non-B non-C hepatocellular carcinoma
(NBNC-HCC). The reported prevalence of NBNC-HCC
ranged between 5-15% [5-7]. The viral marker negative
* Correspondence: amna.subhan@aku.edu
1Section of Gastroenterology, Department of Medicine, The Aga Khan
University & Hospital, Stadium Road, Karachi 74800, Pakistan
Full list of author information is available at the end of the article
© 2013 Butt et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Butt et al. BMC Research Notes 2013, 6:137
http://www.biomedcentral.com/1756-0500/6/137
HCC is attributable to alcoholic liver injury, autoimmune
and metabolic liver diseases, exposure to environmental
toxins like aflatoxins B1 and nonalcoholic steatohepatitis
(NASH) (5). Since diverse oncogenic pathways are in-
volved, difference exists in natural course and outcome of
HCC in these two groups [8-10]. Hence, considering the
fact that HBV has a more direct carcinogenic activity,
most of HBV related HCC, present at an earlier stage of
cirrhosis, with more aggressive tumors as compared to
HCV related HCC [11,12]. Likewise it is well expected
that the difference exist in natural history and prognosis
of HCC due to viral and non-viral etiologies [3,13]. None-
theless, one should not ignore the fact that there have
been few reports regarding viral marker negative HCC
which are mostly based upon unselected or post-surgical
patients without stratification according to age, liver func-
tion, tumor stage and modality of cancer diagnosis
[12,14]. Furthermore, the data regarding HCC due to
HBV or HCV or hepatitis D (HDV) co-infection is scanty
[2]. Therefore, it is of significance that this issue be
addressed on a broader scale.
Pakistan is located in the region that is known to have
intermediate prevalence for HCV and HBV [2]. However,
the data available in Pakistan on HCC is limited and
mainly encompasses experiences from a single center
with a small sample size and largely emphasizing on
viral-HCC. Based upon these results, HCV is the leading
cause of HCC in Pakistan followed by HBV [2,15-18].
Furthermore, no data is available on prevalence and
prognostic factors of viral marker negative hepatocellular
carcinoma in Pakistan. Hence, this study was conducted
to (1) investigate the trends and clinico-pathological char-
acteristics of Hepatocellular carcinoma among native
South Asian Pakistani patients, and (2) to estimate the
prevalence and trends of viral marker negative HCC and
(3) to compare the clinico-pathological, radiological
characteristics, stage of HCC, applicability of treatment
at diagnosis and prognostic factors among native South
Asian patients in Pakistan with viral marker negative and
viral-HCC being consulted at The Aga Khan University
Hospital (AKUH), Karachi, Pakistan.
Methods
Study population and duration
This was a retrospective cross sectional study. Patients ≥ 18
years, diagnosed to have HCC, visiting the Gastroenter-
ology ward and clinics, of AKUH from January 1999 to
December 2009 were identified from our data base by
using ICD code 1550. AKUH is a 563 bedded, largest
tertiary care hospital in the metropolitan city of Karachi
with a population of 18 million [7]. The medical record
coders at AKUH assign numerical codes for diseases
and procedures to all records in accordance with stan-
dards outlined in the International Classification of
Diseases (ICD-9-CM) code book. The information was
recorded on demographics, etiology of underlying
chronic liver disease, clinical, radiological, histological
characteristics and stage of HCC at the time of diagno-
sis and the initial treatment provided. Cases with any of
this missing information were excluded.
Diagnosis of HCC and cirrhosis
The diagnosis of HCC was made with characteristic fea-
tures of HCC on triple-phase computerized tomography
(CT) scan/magnetic resonance imaging (MRI) or when
the concurrent results were found on CT scan/MRI, in
the presence of background chronic liver disease, with
or without histological verification [1,19]. The presence
of arterial enhancement, followed by washout of contrast
on porto-venous and delayed phase were considered as
typical characteristic features of HCC [1,19]. The diag-
nosis of cirrhosis was made either on liver biopsy or, in
the absence of liver biopsy by clinical and laboratory fea-
tures of portal hypertension i.e. varices on upper gastro-
intestinal endoscopy, radiological features suggestive of
cirrhosis including nodular liver margins, dilated portal
vein, spleenomegaly and ascites [20,21]. The Child-Pugh
classification was used to define the severity of liver
dysfunction [22]. Modality of HCC diagnosis was defined
(i) under surveillance, when it was detected during regular
semiannual screening by ultrasound and alfa fetoprotein
(AFP), (ii) incidental, when an asymptomatic HCC was
discovered outside any surveillance program or during
diagnostic procedures performed for some other disease,
(iii) symptomatic when HCC was diagnosed during
workup after symptom appearance.
Staging and classification of HCC
The HCC was considered as “nonadvanced” (if the lesion
was solitary, ≤5 cm or paucifocal ≤3 lesions, with the largest
diameter ≤3 cm, in the absence of vascular invasion and
distant metastases) and “advanced,” when the tumor
exceeded these limits. Okuda classification was also used to
stage HCC [23]. Moreover, the HCC was also classified
according to macroscopic types as (i) solitary, (ii) paucifocal
(≤3 nodules), (iii) multifocal (>3 nodules), (iv) infiltrative
(infiltrating pattern of HCC) or massive (huge mass with a
diameter of > 10 cm and an undefined boundaries) [24]. In
the presence of ≥2 lesions, the largest tumor was consid-
ered as the representative HCC and the diameter of the
representative tumor was measured in its greatest dimen-
sion and recorded as tumor size.
The tumor size was divided into three groups; (i) <5 cm
(ii) 5-10 cm and (iii) > 10 cm. Furthermore, information
was recorded regarding hepatic lobes involved; presence
of portal vein thrombosis and extra hepatic spread.
The Milan criteria were used to define the stage of
HCC while evaluating for liver transplantation [19,25].
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Moreover, allocation of various treatment options were
according to the Barcelona-Clinic Liver Cancer (BCLC)
staging classification [26].
Laboratory parameters
Liver function tests i.e. total bilirubin, serum alanine ami-
notransferase (ALT), serum albumin, prothrombin time
(PT) and serum alpha-fetoprotein (AFP) were recorded.
Viral markers for Hepatitis B (HBsAg) and C (anti-HCV
antibody) were tested by radioimmunoassay or enzyme-
linked immunosorbent assay (ELISA).
Moreover, information was collected regarding co-
morbid conditions i.e. Diabetes Mellitus (DM); hyperten-
sion; dyslipidemia; complications related to cirrhosis;
histological findings on liver biopsy and initial treatment
provided for HCC.
Main outcome measures and potential prognostic factors
We investigated the trends of HCC during the afore-
mentioned time period. The patients were divided into
two groups i.e. i) Viral marker negative HCC (those who
have undetectable viral markers for both hepatitis B and
C i.e. HBsAg and Anti-HCV antibody) and ii) Viral-
HCC or viral marker positive HCC (in whom hepatitis B
or C or D was detected by HBsAg, anti-HCV antibody
or anti-HDV antibody). Patient’s demographic features,
clinical, biochemical, histological, radiological character-
istics, stage of HCC and applicability of initial treatment
provided, were compared between these two groups.
Clinical, laboratory parameters compared include demo-
graphic characteristics, body mass index (BMI), co-
morbid conditions, duration from diagnosis of CLD to
diagnosis of HCC, complications due to cirrhosis, Child-
Turcotte-Pugh (CTP) score and class, Okuda class,
mode of diagnosis, AFP, total bilirubin, ALT, PT, plate-
lets count at baseline, histopathology, radiological fea-
tures of HCC (location, size/median diameter, number
of lesions), macroscopic types, HCC stage, vascular inva-
sion, extra hepatic metastasis and treatment provided
were compared as potential prognostic factors between
the two groups.
The study was conducted by maintaining compliance
with the Helsinki Declaration and was approved by the
Ethical review committee of AKUH.
Statistical analysis
Data was entered and analyzed using SPSS version 17.0.
Mean ± SD, ranges were calculated for continuous vari-
ables and proportions for categorical variables. To see
the trends of HCC, year wise frequencies of HCC cases
were also calculated. To see the difference between the
two groups independent student t-test, chi square and
Fisher exact were used where appropriate. Continuous
variables were checked for their linearity, by doing
quartile and Box Tidwell analysis. Dummy variables were
created for variables with more than two categories and
the reference group for each variable was defined as the
category with the minimal risk for HCC using previous
studies. Multi-colinearity was checked among all the in-
dependent variables. A univariate logistic regression ana-
lysis was conducted to assess the (crude) association of
the prognostic factors for viral-HCC vs. viral marker
negative HCC. Biological significance and a value of p ≤
0.25 were considered as criteria for a variable to be sig-
nificant at univariate analysis. Biological plausible inter-
actions among variables and confounding were also
checked. The variables found significant on univariate
analysis were included in multivariable logistic regres-
sion analysis. Multivariable logistic regression was done
and results expressed as odds ratios, along with 95%
confidence intervals.
Later, multinomial logistic regression was done [27];
this analysis allowed for a reference category (HCV) to
be compared with other categories (HBV, HBV/HCV/
HDV co-infection and viral marker negative HCC). This
was used to assess the influence of several independent
factors, as well as to study the effects of specific vari-
ables controlled by confounders. Biological significance
and a value of p ≤ 0.25 were considered as criteria for a
variable to be significant at univariate analysis. P value
of < 0.05 was considered significant and multinomial
odds ratios (mOR) were calculated.
Results
Trends and clinic-pathological characteristics of HCC
A total of 700 consecutive patients with HCC visited
AKUH during 1999 and 2009. Out of these 700 patients,
645 (92%) fulfilled the eligibility criteria and were stud-
ied. During the entire study period, an almost consistent
increase in number of all HCC cases as well as the viral
marker negative HCC cases diagnosed was observed
(Figure 1 and 2). The demographic and clinico-
pathological characteristics of all HCC patients were as
described in Table 1. Majority (70.9%) of our subjects
were males. Mean age at inclusion was 56.93 ± 11.15
years (range 18–95 years). There were 546 (84.7%) viral-
HCC and 99 (15.3%) viral marker negative HCC. Among
viral-HCC group the underlying etiology of cirrhosis was
HCV in majority (57.3%) of the cases followed by HBV
(18.4%). Concomitant hepatitis B and D or hepatitis B
and C were found in 8.7% of all HCC cases. Mean BMI
was 24.55 ± 4.39 Kg/m2. None among all cases were
found as heavy drinkers (i.e. alcohol consumption more
than 40 gr/day).
Majority of our patients had a Child’s class B or C cir-
rhosis. Almost two third (74.4%) of all patients experi-
enced at least one complication related to cirrhosis
before their index presentation. Concomitant diabetes,
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hypertension or dyslipidemia was found in 40.2%, 34.4%
and 2.5% of the cases, respectively. Most of the HCC
cases (82.9%) were diagnosed when they were symptom-
atic, while only 8.2% HCC cases were diagnosed on
screening. The duration between diagnosis of chronic
liver disease and HCC was 24.01 ± 38.05 months (range
0–195 months). Moreover, majority of patients (62.8%)
had advanced HCC. The average maximum tumor size
was 5.62 ± 3.67 cm.
Comparison of viral-HCC and viral marker negative HCC
We compared the demographic and clinical characteris-
tics of patients with viral-HCC and viral marker negative
HCC (Table 1). Patients with viral marker negative HCC
Figure 2 Distribution of viral-HCC and viral marker negative HCC during 1999–2009.
Figure 1 Year wise trends of HCC cases during 1999 till 2009.
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Table 1 Demographic and clinical characteristics of all HCC patients and comparison of viral-HCC vs. viral marker
negative HCC
ALL HCC cases Comparison of viral-HCC vs. viral marker negative HCC mean ± SD/%
n = (645), mean ± SD/%
Viral-HCC (n = 546) Viral marker negative HCC (n = 99) P value
Age(years) 56.93 ± 11.15 56.46 ± 10.85 59.57 ± 12.45 0.01
Gender
Female 29.1 29.9 25.3 0.34
Male 70.9 70.1 74.7
BMI (Kg/m2)
<18 6.2 5.5 10.1
18-22.9 28.1 28.6 25.3 0.24
23-24.9 23.6 22.9 27.3
≥25 42.2 43.0 37.4
Diabetes Mellitus
No 59.8 61.7 49.5 0.02
Yes 40.2 38.3 50.5
Hypertension
No 65.6 66.8 58.6 0.11
Yes 34.4 33.2 41.4
Dyslipidemia
No 97.5 97.4 98.0 0.74
Yes 2.5 2.6 2.0
Child score 9.29 ± 2.31 9.27 ± 2.29 9.40 ± 2.43 0.59
Child class
A 12.6 12.8 11.1 0.50
B 42.3 43.0 38.4
C 45.1 44.1 50.5
Okuda class
I 14.3 14.3 14.1 0.97
II 61.4 61.5 60.6
III 24.3 24.2 25.3
Complication of CLD
No 25.6 26.2 22.2 0.39
Yes 74.4 73.8 77.8
Hyperspleenism
No 37.8 36.6 44.4 0.14
Yes 62.2 63.4 55.6
Ascites
No 31.5 31.3 32.3 0.84
Yes 68.5 68.7 67.7
PSE
No 65.9 66.8 60.6 0.23
Yes 34.1 33.2 39.4
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Table 1 Demographic and clinical characteristics of all HCC patients and comparison of viral-HCC vs. viral marker
negative HCC (Continued)
Esophageal varices
No 47.0 46.3 50.5 0.44
Yes 53.0 53.7 49.5
Upper GI bleed
No 59.5 59.2 61.6 0.64
Yes 40.5 40.8 38.4
Hepatohydrothorax
No 91.0 91.4 88.9 0.43
Yes 9.0 8.6 11.1
Hepatorenal syndrome
No 77.4 77.8 74.7 0.50
Yes 22.6 22.2 25.3
Hepatopulmonary syndrome
No 92.2 92.9 88.9 0.19
Yes 7.8 7.1 11.1
Total Bilirubin(mg/dl)
<2 50.2 50.7 47.5 0.48
2-3 20.5 20.9 18.2
>3 29.3 28.4 34.3
Albumin(mg/dl)
>3.5 8.1 7.7 10.1 0.73
2.8-3.5 29.3 29.5 28.3
<2.8 62.6 62.8 61.6
ALT (IU/ml)
Normal 30.23 28.4 40.4 0.19
Elevated 69.77 71.6 59.6
Prothrombin time(seconds)
No 92.2 92.9 88.9 0.19
Yes 7.8 7.1 11.1
Total Bilirubin(mg/dl)
<2 50.2 50.7 47.5 0.48
2-3 20.5 20.9 18.2
>3 29.3 28.4 34.3
Albumin(mg/dl)
>3.5 8.1 7.7 10.1 0.73
2.8-3.5 29.3 29.5 28.3
<2.8 62.6 62.8 61.6
ALT (IU/ml)
Normal 30.23 28.4 40.4 0.19
Elevated 69.77 71.6 59.6
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were significantly older (p 0.01) and almost half of them
were affected by concomitant DM (50.5% vs. 38.3%, p 0.02)
as compared to viral-HCC. No difference was found in
distribution of gender, BMI, severity and complications
of cirrhosis, associated co-morbid conditions, biochem-
ical profile and AFP levels. However, patients with viral
HCC were more thrombocytopenic than viral marker
negative HCC on presentation (p <0.001).
There was no difference in proportion of patients diag-
nosed with HCC when symptomatic in viral-HCC and
viral marker negative HCC group (82.4% vs. 85.9%).
Overall only 8.2% HCC cases were diagnosed on screen-
ing. However, in contrary to viral-HCC group, small
number of patients with viral marker negative HCC were
under surveillance (1% vs. 9.5%, p 0.001). It’s not correct
to compare HCC in followed patients with those who
were not under surveillance for HCC. However, as we
found a very small proportion of patients with HCC who
were under surveillance, we felt better to see the differ-
ence among both group. In 65.7% of non-viral HCC and
41.4% of viral HCC diagnosis of cirrhosis and HCC were
made simultaneously. Hence, the duration between diag-
nosis of cirrhosis and HCC was significantly shorter in
viral marker negative HCC group as compared to viral-
HCC (p <0.001). This was probably due to the fact that
a greater proportion of patients with non-viral HCC was
not symptomatic and was not under surveillance for
HCC as compared to viral HCC cases. Not only the
tumor size was significantly larger (p <0.001), but HCCs
were more advanced at presentation in viral marker
negative HCC group as compared to viral-HCC (81.8%
vs. 59.3%, p < 0.001). No difference was found in the
involvement of hepatic lobes, presence of PVT and
extra-hepatic spread among both the groups (Table 2).
On univariate logistic regression analysis older age, male
gender, concomitant DM & HTN, hypersplenism, PSE,
HRS, elevated ALT, platelets counts, duration between
diagnosis of cirrhosis and HCC, modality of diagnosis,
stage, size and macroscopic types of HCC, presence of
extra hepatic spread were found as significant independ-
ent prognostic factors (Table 3). However, when adjusted
for other independent prognostic factors; larger tumor
size (p <0.001), shorter duration between diagnosis of cir-
rhosis and HCC (p 0.03), concomitant DM (<0.001) were
found significant factors associated with viral marker
negative HCC (Table 4).
Comparison of viral marker negative HCC with HCC due
to hepatitis B, C, or combination of viruses
Table 5 depicts, unadjusted odds ratios along with 95% CI.
Analysis showed that with HCV as reference, the male gen-
der was significantly associated with HBV, co-infections
and viral marker negative HCC. The tumor size of 5–10
cms, was also significantly associated with HCC due to
hepatitis B and with viral maker negative HCC versus
HCV. However, variables like extra hepatic spread, compli-
cations of cirrhosis, Child’s score, Okuda score, were not
found significant on univariate analysis.
The multivariable analysis showed that, the males had a
greater risk of developing HCC due to hepatitis B, co-
infections due to HBV/HCV/HDV (mOR 2.3, 2.6, 1.5
respectively) as compared to females. The risk of being di-
agnosed when symptomatic was 4.1 times and 8.1 times
higher in case of HBV related HCC and viral marker nega-
tive HCC respectively (mOR 4.1 and 8.1 respectively) as
compared to HCV related HCC. Tumor size >5 cm, was
only found to be significantly associated with viral marker
negative HCC. Likewise, the risk of being diagnosed to
have underlying cirrhosis and HCC simultaneously at pres-
entation was higher in case of HBV and viral marker
negative HCC (mOR 3.7 and 3.0 respectively). Moreover,
BMI <18 was significantly associated with HCC due to
hepatitis B and viral marker negative HCC (mOR 2.8 and
3.1). This could be attributed to malnutrition and weight
loss due to more advanced HCC in these cases. However,
HBV and HCV were less likely when BMI was ≥ 25 (mOR
0.6 and 0.9). Furthermore, the odd of having diabetes was
1.6 times higher in NBNC compared to HCV related HCC.
Applicability of treatment for HCC
According to the Barcelona Clinic Liver Cancer (BCLC)
staging classification 9(1.4%) patients had very early
Table 1 Demographic and clinical characteristics of all HCC patients and comparison of viral-HCC vs. viral marker
negative HCC (Continued)
Prothrombin time(seconds)
<3 42.8 41.6 49.5 0.14
3-6 34.6 36.1 26.3
>6 22.6 22.3 24.2
Platelets counts(109/L) 165.91 ± 107.02 155.72 ± 96.33 222.12 ± 141.01 <0.001
AFP(IU/ml)
≤200 58.8 58.2 61.6 0.30
>200 41.2 41.8 38.4
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stage (0) HCC; 2(0.3%) of them underwent liver trans-
plantation and 7(1.1%) had tumor resection. Moreover, 9
(1.4%) patients had early stage HCC (A) and they had
percutaneous ethanol ablation (PEA). However none
HCC patients in BCLC stage 0 or stage A belonged to
viral marker negative HCC group. This was due to the
fact that majority of viral marker negative HCC patients
(81.8%) had advanced HCC on presentation.
A total of 260(40.3) patients had BCLC-Intermediate
stage (B) HCC out of which Transarterial chemoem-
bolization (TACE) was done in 247 (38.3%) cases; out of
these 247 cases only 13.37% had viral marker negative
HCC. BCLC-advanced stage (C) HCC was found in 8
(1.2%) HCC cases (six had viral- HCC and two had non-
viral HCC) where either Gemcitabine or Sorafenib was
prescribed as chemotherapeutic agent. Overall 372 (57.7%)
patients were treated conservatively due to underlying
advanced cirrhosis/HCC (BCLS stage End stage (D)) or
contraindication for HCC treatment. Hence, the applicabil-
ity of treatment for HCC was limited for viral marker
negative HCCs due to underlying advanced cirrhosis and
HCC at presentation.
Discussion
Hepatocellular carcinoma is a major concern globally
and to the best of our knowledge, this is the largest
Table 2 Characteristics of HCC and comparison of tumor characteristics among viral-HCC vs. viral marker negative HCC
ALL HCC cases Comparison of viral-HCC vs. viral marker negative HCC
n = (645)
Mean ± SD/n (%) Viral HCC (n = 546) Viral marker negative HCC(n = 99) P value
Duration between diagnosis
of cirrhosis & HCC(months)
00 291(45.1) 226(41.4) 65(65.7) <0.001
1-55 243(37.7) 219(40.1) 24(24.2)
>55 111(17.2) 101(18.5) 10(10.1)
Mode of diagnosis
On screening 53(8.2) 52(9.5) 1(1.0) 0.001
Incidental 57(8.8) 44(8.1) 13(13.1)
Symptomatic 535(82.9) 450(82.4) 85(85.9)
Stage of HCC
Non-advance 240(37.2%) 222(40.7) 18(18.2) <0.001
Advance 405(62.8%) 324(59.3) 81(81.8)
Macroscopic types
Solitary 246(38.1) 213(39.0) 33(33.3) 0.04
Paucifical (≤ 3 nodules) 259(40.2) 223(40.8) 36(36.4)
Multifocal(>3 nodules) 96(14.9) 79(14.5) 17(17.2)
Massive/infiltrative 44(6.8%) 31(5.7) 13(13.1)
Maximum tumor size (cm)
< 5 359(55.65) 326(59.7) 33(33.3) <0.001
5-10 213(33.02) 173(31.7) 40(40.4)
>10 73(11.31) 47(8.6) 26(26.3)
Hepatic lobes
Left 81(12.6) 69(12.6) 12(12.1) 0.98
Right 387(60) 327(59.9) 60(60.6)
Both 177(27.4) 150(27.5) 27(27.3)
PVT
No 429(66.5) 359(65.8) 70(70.7) 0.33
Yes 216(33.5) 187(34.2) 29(29.3)
Extra hepatic spread
No 560(86.8) 479(87.7) 81(81.8) 0.12
Yes 85(13.2) 67(12.3) 18(18.2)
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Table 3 Univariate analysis for prognostic factors of viral-HCC vs. viral marker negative HCC
Variables OR(95% CI) P value Variables OR(95% CI) P value
Age(years) 1.026(1.01-1.05) 0.01 Hepatopulmonary Syndrome
Gender No 1.0 0.19
Female 1.0 0.34 Yes 1.62(0.80-3.29)
Male 1.26(0.77-2.05) Total Bilirubin(mg/dl)
BMI (Kg/m2) <2 1.0 0.48
18-22.9 1.0 0.24 2-3 0.93(0.51-1.67)
<18 2.08(0.90-4.77) >3 1.29(0.79-2.09)
23-24.9 1.34(0.74-2.43) Albumin(mg/dl)
≥25 0.98(0.56-1.69) >3.5 1.0 0.73
Diabetes Mellitus 2.8-3.5 0.73(0.32-1.62)
No 1.0 0.02 <2.8 0.74(0.35-1.56)
Yes 1.64(1.07-2.53) ALT (IU/ml)
Hypertension Normal 1.0 0.19
No 1.0 0.11 Elevated 0.58(0.37-0.91)
Yes 1.42(0.92-2.21) Prothrombin time(second)
Dyslipidemia <3 1.0 0.14
No 1.0 0.74 3-6 0.61(0.3-1.02)
Yes 0.74(0.17-3.50) >6 0.91(0.53-1.55)
Child score 1.02(0.93-1.12) 0.59 Platelets counts (109/L) 1.01(1.0-1.01) <0.001
Child class AFP(IU/ml)
A 1.0 0.50 ≤200 1.0 0.53
B 1.02(0.50-2.11) >200 0.86(0.56-1.34)
C 1.32(0.65-2.67) Duration between diagnosis
of cirrhosis
Okuda class 00 2.90(1.43-5.88) <0.001
I 1.0 0.97 1-55 1.10(0.51-2.40)
II 0.99(0.52-1.87) >55 1.0
III 1.15(0.51-2.15) Mode of diagnosis
Complication of CLD On screening 1.0 0.001
No 1.0 0.39 Incidental 15.36(1.93-122.14)
Yes 1.24(0.74-2.07) Symptomatic 9.82(1.34-72.01)
Hyperspleenism Stage of HCC
No 1.0 0.14 Non-Advance 1.0 <0.001
Yes 0.72(0.46-1.11) Advance 3.08(1.79-5.28)
Ascites Macroscopic types of HCC
No 1.0 0.84 Solitary 1.0 0.04
Yes 0.95(0.60-1.51) Paucifocal (≤ 3 nodules) 1.04(0.62-1.73)
PSE Multifocal(>3 nodules) 1.38(0.73-2.63)
No 1.0 0.23 Massive/infiltrative 2.7(1.28-5.69)
Yes 1.31(0.84-2.03) Maximum tumor size(cm)
Esophageal Varices < 5 1.0 <0.001
No 1.0 5-10 2.08(1.39-3.75)
Yes 0.84(0.55-1.29) 0.44 >10 5.46(3.01-9.93)
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study from Pakistan carried out on HCC ever. We ana-
lyzed the trends and the clinico-pathological characteris-
tics of HCC; comparing them between HCC related to
viral hepatitis and viral marker negative HCC; in our na-
tive South Asian population of Pakistan. A consistent
rise in proportion of all, including viral marker negative
HCC has been observed and a higher proportion of pa-
tients (15.3%) had HCC negative for serological markers
of hepatitis B and C. Being not under proper surveil-
lance for HCC, most of the viral marker negative HCCs
were diagnosed when advanced and symptomatic. More-
over, significant association was found between DM and
viral marker negative HCC. The variation from HBV to
HCV as a leading cause of HCC has also been docu-
mented in many countries of South-east Asia [2]. Also, a
gradual rise in NBNC-HCC has been observed in recent
years. In a recent study from Japan, out of 1374 HCC
cases 15% were negative for HBsAg and antibody to
hepatitis C virus and a significant association of Dia-
betes, HTN and dyslipidemia was established with
NBNC-HCC [28]. In few small studies from Pakistan the
reported proportions of viral marker negative HCC
ranged between 13.6%-16% [29,30]. Our results are con-
sistent with the studies reported from the region with a
potential strength of greater generalizability due to a lar-
ger sample size. However, the higher prevalence of viral
marker negative HCC has been found in certain studies
conducted in Western populations [31-33] which could
be due to the existing difference in exposure to the vari-
ous etiological factors leading to HCC.
HCCs at the early-stage are usually asymptomatic, and
are mostly discovered during periodic surveillance. It be-
ing diagnosed when symptomatic, increases the risk of
having more advance disease when caught, with worse
prognostic factors [1], as seen in our study. In 65.7% of
non-viral HCC and 41.4% of viral HCC diagnosis of cir-
rhosis and HCC were made simultaneously. Our results
were consistent with the study conducted by Toyoda
and colleagues [3] where out of 1152 Japans patients
with HCC, 10.3% had NBNC-HCC. NBNC-HCCs were
more advanced, larger in size and associated with more
frequent vascular invasion and extrahepatic spread at
the time of diagnosis. Moreover, almost half of NBNC-
HCC cases were not under surveillance as compared to
viral HCC (42 vs. 22.9%, p <0.0001). In another study of
624 patients from Japan [34] viral marker negative HCCs
were found to be associated with poor prognosis. Fur-
thermore, male gender, Child’s core, TNM stage were
the significant prognostic factors in that study. In our
study we observed shorter time interval between the
diagnosis of cirrhosis and HCC, more advanced, larger,
multifocal, massive or infiltrative tumors in case of viral
marker negative HCC as compared to viral HCC. This
was probably due to the fact that most of patients with
non-viral HCC were not symptomatic and were not
under surveillance for HCC. While due to better aware-
ness about the risk of cirrhosis and HCC associated with
hepatitis B and C, most of such patients were diagnosed
to have cirrhosis earlier than HCC diagnosed. Thus, due
to lack of surveillance, most of NBNC-HCC were diag-
nosed when symptomatic leading to a later diagnosis.
Table 3 Univariate analysis for prognostic factors of viral-HCC vs. viral marker negative HCC (Continued)
Upper GI bleed Hepatic Lobes
No 1.0 Left 1.0 0.98
Yes 0.90(0.58-1.40) 0.64 Right 1.05(0.53-2.06)
Hepatohydrothorax Both 1.03(0.49-2.16)
No 1.0 0.43 Porto Venous Thrombosis
Yes 1.32(0.66-2.65) No 1.0 0.33
Hepatorenal Syndrome Yes 1.25(0.788-2.00)
Extra hepatic spread
No 1.0 0.50 No 1.0 0.12
Yes 1.18(0.72-1.94) Yes 1.58(0.89-2.81)
Table 4 Multivariable logistic regression analysis for
prognostic factors of viral-HCC vs. viral marker negative
HCC
OR(95% CI) P value
Maximum tumor size(cm)
< 5 1.0 <0.001
5-10 2.28(1.37-3.81)
>10 5.30(2.82-9.96)
Duration between diagnosis of cirrhosis and HCC (months)
00 2.56(1.23-5.34) 0.02
1-55 1.14(0.51-2.52)
>55 1.0
Diabetes Mellitus
No 1.0 <0.00
Yes 1.94(1.23-3.07)
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The patients with viral marker negative HCCs tended to
be older and diabetic as compared to the viral HCC.
However, no significant difference was found in distribu-
tion of gender, BMI, stage of underlying chronic liver
disease in our study.
Owing to the involvement of distinct oncogenic path-
ways in the development of HCC, it is well expected that
difference exists in the natural course of HCC and prog-
nosis due to different hepatotropic viruses and other
non-viral etiologies [3,13]. In a study by Dohmen and
colleagues [5] younger age, HCC >3 cm in size, multiple
lesions, PVT were strongly associated with HBV related
HCC as compared to HCC due to HCV and non-viral
HCC. Poor survival was found for HBV related HCC
and NBNC-HCC had a longer survival rate. Similar re-
sults were found in another study of 2,542 HCC patients
from Japan [13]. Trevisani and colleagues compared the
HBV, HCV, alcohol and multietiology (combination of
different hepatotropic viruses with and without alcohol)
related HCC among 742 Italian HCC patients [35]. In
their study, infiltrative HCCs were found more common
in HBV-HCC group; and CLIP stage 3 was more
frequent in HBV and multietiology group. However, the
influence of etiology of gross pathology was not signifi-
cant. In our study, regardless of underlying etiology a
significant association of male gender was found with
HCC. HBV-HCC and viral marker negative HCCs were
found to be more advanced and aggressive at the time of
presentation. Most of them were more symptomatic,
larger in size and were diagnosed simultaneously with
the underlying cirrhosis. These findings support the
greater carcinogenic activity of hepatitis B and non-viral
etiologies. We did not find any strong associations in
clinico-pathological characteristics and stage of HCC in
co-infection group. This could be due to small sample of
patients in co-infection group. Diabetes had a significant
association with viral marker negative HCC which could
be due to underlying non-alcoholic steatohepatitis.
Table 5 Comparison of viral marker negative HCC with HCV-HCC, HBV-HCC, combination-HCC
Percentages Unadjusted OR(95% CI) Adjusted OR(95% CI)
Variable HCV HBV Combination NBN HBV Combination NBNC HBV NBNC Combination
Gender
Female 35.6 17.6 17.9 25.3 1 1
Male 64.4 82.4 82.1 74.7 2.5 (1.5-4.3) 2.5 (1.2-5.1) 1.6 (0.9-2.6) 2.3 (1.3-3.8) 1.5 (0.8-2.5) 2.6 (1.2-5.3)
Diagnosis of
HCC
On screening 11.9 2.5 1.9 1.0 1 1
incidental 8.1 9.2 5.4 13.1 5.3 (1.3-20.9) 0.88 (0.19-3.96) 19.06 (2.3-153.5) 3.4 (0.8-13.9) 10.1 (1.2-84.7) 0.8 (0.17-3.8)
symptomatic 80.1 88.2 85.7 85.9 5.1 (1.5-17.0) 1.4 (0.53-3.76) 12.5 (1.7-92.7) 4.1 (1.2-13.9) 8.1 (1.1-60.3) 1.4 (0.5-3.9)
BMI (Kg/m2)
18-22.9 26.7 35.3 26.8 25.3 1 1
<18 3.8 11.8 3.6 10.1 2.3 (1.03-2.37) 0.94 (0.19-4.56) 2.8 (1.12-7.11) 2.8 (1.2-6.6) 3.1 (1.1-8.3) 1.1 (0.2-5.0)
23-24.9 22.9 21.0 26.8 27.3 0.69 (0.39-1.23) 1.16 (0.53-2.52) 1.25 (0.53-2.52) 0.7 (0.3-1.3) 1.3 (0.6-2.4) 1.1 (0.5-2.4)
≥ 25 46.6 31.9 42.9 37.4 0.51 (0.31-0.85) 0.91 (0.45-1.82) 0.84 (0.48-1.48) 0.6 (0.3-1.1) 0.9 (0.5-1.7) 1.0 (0.5-2.0)
Maximum
diameter (cm)
<5 62.5 49.6 62.5 33.3 1 1
5-10 29.1 39.5 32.1 40.5 1.7 (1.09-2.6) 1.1 (0.59-2.0) 2.6 (1.5-4.3) 1.5 (0.9-2.5) 2.3 (1.3-4.0) 0.9 (0.5-1.7)
>10 8.4 10.9 5.4 26.3 1.64 (0.8-3.3) 0.64 (0.18-2.2) 5.8 (3.1-11.1) 1.0 (0.5-2.2) 4.0 (2.0-7.9) 0.5 (0.1-1.7)
Duration between
diagnosis of CLD
and HCC
>55 22.1 6.7 19.6 10.1 1 1
zero 37.5 52.1 44.6 65.7 4.5 (2.0-10.0) 1.3 (0.62-2.8) 3.8 (1.8-7.8) 3.7 (1.6-8.4) 3.0 (1.4-6.5) 1.1 (0.4-2.4)
1-55 40.4 41.2 35.7 24.2 3.3 (1.5-7.4) 0.9 (0.4-2.1) 1.3 (0.5-2.8) 2.6 (1.1-6.1) 1.2 (0.5-2.8) 0.7 (0.3-1.7)
Diabetes
No 55.8 72.3 78.6 49.5 1 1
Yes 44.2 27.7 21.4 50.5 0.48 (0.30-0.76) 0.34 (0.17-0.67) 1.2 (0.8-2.0) 0.5 (0.3-0.9) 1.6 (0.1-2.5) 0.3 (0.2-0.6)
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The studies describing the characteristics and progno-
sis of viral marker negative HCC are limited and most
involved the patients who underwent hepatic resection,
selected as the study population; hence, might not truly
reflect the entire population of viral marker negative
HCC [5,36,37]. Differences exist in exposure to the vari-
ous etiological factors for HCC and host factors in Asian
population as compared to West. However, limited data
is available from South-Asia. Our study comprises a
large sample of patients referred from all over the coun-
try and reflects well the scenario of HCC in patients
with cirrhosis belongs to a South Asian community.
However, our study has certain limitations. It is a single
center based, cross sectional study; therefore the true
cause and effect relationship could not be ascertained.
Furthermore, for the analysis of HBV infection, HBsAg
was tested while HBeAg, Anti-HBe, Anti-HBc, Anti-HBs
, and HBV DNA were not checked. In majority of cases
further work to evaluate HBV infection and viral replica-
tion was not offered by their primary physicians. Hence,
only serological marker for HBV exposure available was
HBsAg. Moreover, due to its cross sectional design des-
pite large sample there are certain biases. Most of our
patients with unresectable HCC were diagnosed inciden-
tally or when they were symptomatic. Hence, the true
interval between disease progression from exposure to
development of HCC could not be established. For
consistency of results, better exploration of natural his-
tory, and prognosis of HCC in the South-Asian popula-
tion, population based studies are needed.
Conclusion
To conclude, the burden of hepatocellular carcinoma is
on the rise amongst native South Asian Pakistani popula-
tion and viral marker negative HCC is not uncommon
here. Patients with viral marker negative HCC tend not to
be under surveillance as compared to viral-HCC and are
diagnosed mostly with a more advanced disease when
symptomatic. Hence, viral marker negative HCC (vs. viral-
HCC) were more advanced, larger in size, mostly multi-
focal, massive or infiltrative at the time of presentation.
Moreover, viral marker negative and HBV related HCC
were more symptomatic, advanced with larger tumor size
on presentation as compared to HCC due to HCV or co-
infection with HBV/HCV/HDV. Diabetes Mellitus was
found to be a significant factor associated with viral marker
negative HCC. We believe that it is of great importance
that ample light be shed on the need for strategies that can
help in implementation of proper screening and surveil-
lance of HCC for all cirrhotic patients especially when
cirrhosis is due to non-viral etiologies.
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